Small RNA combination therapy for lung cancer
نویسندگان
چکیده
منابع مشابه
Small RNA combination therapy for lung cancer.
MicroRNAs (miRNAs) and siRNAs have enormous potential as cancer therapeutics, but their effective delivery to most solid tumors has been difficult. Here, we show that a new lung-targeting nanoparticle is capable of delivering miRNA mimics and siRNAs to lung adenocarcinoma cells in vitro and to tumors in a genetically engineered mouse model of lung cancer based on activation of oncogenic Kirsten...
متن کاملDevelopment of Small RNA Delivery Systems for Lung Cancer Therapy
RNA interference (RNAi) has emerged as a powerful tool for studying target identification and holds promise for the development of therapeutic gene silencing. Recent advances in RNAi delivery and target selection provide remarkable opportunities for translational medical research. The induction of RNAi relies on small silencing RNAs, which affect specific messenger RNA (mRNA) degradation. Two t...
متن کاملDocetaxel/Vinorelbine Combination Therapy in Non-Small-Cell Lung Cancer
Docetaxel (Taxotere) and vinorelbine (Navelbine) are two of a number of new third-generation chemotherapeutic agents that have become available in recent years. A series of single-agent and combination therapy studies are underway to determine the efficacy of these agents in the treatment of patients with non-small-cell lung cancer. Although docetaxel and vinorelbine are considered tubulin-bind...
متن کاملCombination chemotherapy for small cell lung cancer.
Small cell lung cancer (SCLC) disseminates early and has poor prognosis. However, SCLC is highly chemosensitive, thus chemotherapy has been established as the primary mode of treatment. Seventeen patients (15 males and 2 females) with median age of 60 years (range 49 to 74 years) were treated with combination cyclophosphamide 750 mg/m2, adriamycin 40 mg/m2, vincristine 1.4 mg/m2 on day 1 and et...
متن کاملIrinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Lung cancer is the leading cause of cancer-related death in the United States. There was rapidprogress in the treatment of lung cancer duringpast decades, but local control and survival rates are still poor. Radiation therapy has been an indispensable part of the management of lung cancer, and a recent paradigm is concurrent chemoradiation therapy. Many novel chemotherapeutic agents were recent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the National Academy of Sciences
سال: 2014
ISSN: 0027-8424,1091-6490
DOI: 10.1073/pnas.1412686111